{"ticker": {"uuid": "77f997ee-68cd-4c79-8071-0abf825cc700", "symbol": "4883", "name": "Modalis Therapeutics Corporation", "exchange": "JPX", "country": "JP", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Modalis Highlights CRISPR-GNDM Platform as Cornerstone of Rare Disease Growth Strategy", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxPTW15eVpNV0FTODBLeVZiUHBoeDZncTRjaDFKdmlGQW9ISWNIZTVVNk95VXlRR1lwWXItNGFhLXU2LU1ncUJPWVAxVFo4N2pmM09ucGxITWJxNlEwUjBxZzZUWDRlMWFyYXpDeEdnMlYzcnlBNXBQVDVpcE9aVjdCekZkeFM3YmF5a0R3Ml85M0xlcFdmMnRfTV9sOXNPZ1B3dDByaUhsT1NVZ3ZsbHJTc3R2R2I1a2JnbzV2dmE1ZTZiS2pYcF9xdEFTQXVyaWRQd3NCdg?oc=5", "source_name": "TipRanks", "published_at": "2026-07-14T07:08:35+00:00", "published_display": "14 Jul 2026 07:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Modalis Therapeutics Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogJBVV95cUxPekoxOXN0MG1fdDdHakRZaTNMWHVnNi14WGNDUE1oSzVWOHduWUxkWTNsSE55Mm5jMDJDLTE4bXU2Ri1COWpWeWh6S09vZXduOHNiRmRKYWhDaTdhd1NhbTJ2MzlhcFZuN0tiYTlTNzRjZXV1YkhPNTBiMFZoUmVTTmRaRTVJUkdfTWRwODlQTVpBNUFJMXVZVVFoTE9OM2NRak11ck1ybXNEMkM4VUJiVktjVTB0SjY4YmFqbmxnNVRrTFhkZ2RCSW5EX293YlVBZHQtczJ2RDlHMDMzMGp0YVZfSHMtckk2aUR3emZEbnpyWUs4alNBaVRWclZzU1R3amNncGdJRXVmS1NUc0VUUWRJMGFTX0xqSkdfTloxR3BLZw?oc=5", "source_name": "Moomoo", "published_at": "2026-07-04T10:01:02+00:00", "published_display": "04 Jul 2026 10:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Modalis Therapeutics Issues New Shares for Employee Compensation", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOMnQzQzZMN3BzSnYzMUpKcjlWdVhLUEF6VTRTdmk0enRLWThQRjVSaGJsX0hHT0tQZko2QjRZdUFvTjhNdjRuMzJVOVFjZjFpdHhHSVdkLUNrcU9rZHYwRjZpdy1GVVJFYlU0ZWk5VUI0SVNPOG1CdFViaUpkU1pGM1k3WEpzMnhiYkRxM0Z1VGtTWXF4UXRYbzZ3WElGb1NDVGlQcHdpYWdQeXF5a2ZOTU1UV2prZm8?oc=5", "source_name": "TipRanks", "published_at": "2025-06-13T07:00:00+00:00", "published_display": "13 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release Service: JCR Pharmaceuticals and Modalis Therapeutics Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxNT2xmVUFDMXgxQzNiVWs0ZFdIZkJhR0t1QjJuN19CWnJwWjMwZEZTLWZuQlZlZFBvOXBmZFA5OWdjN3dNNmZDV2lKRmlfNzItVVI3cHJEMzEwX09Gam1TalZqOGFvUk12bmFkQVBTZUt5RVhJYUlhcEt6N3FTYW9TN0Z2ek8xejh2enZrQWN2anF6N3c1b1lseVhFYTFIR0FTcmhabHZCMExEQkRia21EaDRxMHluaGY5S01KQk1FM2oweEJqNGNCekhkRC12SHVuUmhjTUJaajJvT0FObWg0MWNibzZrN0RRYlN0bUNQUTY?oc=5", "source_name": "CRISPR Medicine News", "published_at": "2025-01-06T08:00:00+00:00", "published_display": "06 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JCR Pharmaceuticals and Modalis Therapeutics Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgJBVV95cUxNVzhaRlg0bkREUzFiRlFmSjhGTHJtejZOZ2lEdHJicFFiWV94eXpJVEs0SXBKVkFfamdoMnBodVRhRFpEWHZsbG5qdGVMZ1N1QlNHckxPSXd6c09fYzhPWURGWjFheGpiZjF3Z3hxX2hXUzVRcTNhYTZzOG4tc2xHaU5VYUw5QS1zQmtmTFVmenJVT1huVFNCZTlmeEFvSHAwRjlwNU9EYk1SUGp6ZEVzR3Vuck5JQ3NHOC1JVFRsSkh6X3RjNHdyQU42TkhqcnJpN1RBdzFKZlJzdGpJdkRDeE44b2tOZlJnN3owc1l4blJDM2NudjRsQU91Mm9FcjMxT0dvZEFxTWk4aDVlb2RRSHozeXhuU0pxcTExTkI2eXhYT0U4bUZ6VGx3S29LQQ?oc=5", "source_name": "Business Wire", "published_at": "2025-01-05T08:00:00+00:00", "published_display": "05 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release Service: Modalis Therapeutics: FDA Grants Rare Pediatric Disease Designation to MDL-101 for the Treatment of Congenital Muscular Dystrophy Type 1a (LAMA2-CMD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxOak1FRXdfYlVxMjlxekxjYmEtX3g0NnphOTRPWWNFRUV5WG1IOWVVQnhSekoza3JvT2lTWG1meDJCVjZuMnRISFhlRGZGamg0c2JmdDlDSldCWlpFQkd2WnBOMThMaXY4VDRKX2pGSlRxTmU3R3R1UF85a0xQMVhaVVRJcjJsOV9Hc21DeEVOZXpnRENRc1Mta1doamh5dFoyY0Y1UEwyZjBya3A4eEIyR3ZadXFCdThqU0JJNlJBWHVIdDJuQXVaZ0d3Z2F0dDBBV2xMQng3TzZCdGstcnp6bjgxeUc4b1NpSUFYdHhR?oc=5", "source_name": "CRISPR Medicine News", "published_at": "2024-09-30T07:00:00+00:00", "published_display": "30 Sep 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Modalis Highlights CRISPR-GNDM Platform as Cornerstone of Rare Disease Growth Strategy", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxPTW15eVpNV0FTODBLeVZiUHBoeDZncTRjaDFKdmlGQW9ISWNIZTVVNk95VXlRR1lwWXItNGFhLXU2LU1ncUJPWVAxVFo4N2pmM09ucGxITWJxNlEwUjBxZzZUWDRlMWFyYXpDeEdnMlYzcnlBNXBQVDVpcE9aVjdCekZkeFM3YmF5a0R3Ml85M0xlcFdmMnRfTV9sOXNPZ1B3dDByaUhsT1NVZ3ZsbHJTc3R2R2I1a2JnbzV2dmE1ZTZiS2pYcF9xdEFTQXVyaWRQd3NCdg?oc=5", "source_name": "TipRanks", "published_at": "2026-07-14T07:08:35+00:00", "published_display": "14 Jul 2026 07:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Modalis Therapeutics Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogJBVV95cUxPekoxOXN0MG1fdDdHakRZaTNMWHVnNi14WGNDUE1oSzVWOHduWUxkWTNsSE55Mm5jMDJDLTE4bXU2Ri1COWpWeWh6S09vZXduOHNiRmRKYWhDaTdhd1NhbTJ2MzlhcFZuN0tiYTlTNzRjZXV1YkhPNTBiMFZoUmVTTmRaRTVJUkdfTWRwODlQTVpBNUFJMXVZVVFoTE9OM2NRak11ck1ybXNEMkM4VUJiVktjVTB0SjY4YmFqbmxnNVRrTFhkZ2RCSW5EX293YlVBZHQtczJ2RDlHMDMzMGp0YVZfSHMtckk2aUR3emZEbnpyWUs4alNBaVRWclZzU1R3amNncGdJRXVmS1NUc0VUUWRJMGFTX0xqSkdfTloxR3BLZw?oc=5", "source_name": "Moomoo", "published_at": "2026-07-04T10:01:02+00:00", "published_display": "04 Jul 2026 10:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Modalis Therapeutics Issues New Shares for Employee Compensation", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOMnQzQzZMN3BzSnYzMUpKcjlWdVhLUEF6VTRTdmk0enRLWThQRjVSaGJsX0hHT0tQZko2QjRZdUFvTjhNdjRuMzJVOVFjZjFpdHhHSVdkLUNrcU9rZHYwRjZpdy1GVVJFYlU0ZWk5VUI0SVNPOG1CdFViaUpkU1pGM1k3WEpzMnhiYkRxM0Z1VGtTWXF4UXRYbzZ3WElGb1NDVGlQcHdpYWdQeXF5a2ZOTU1UV2prZm8?oc=5", "source_name": "TipRanks", "published_at": "2025-06-13T07:00:00+00:00", "published_display": "13 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release Service: JCR Pharmaceuticals and Modalis Therapeutics Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxNT2xmVUFDMXgxQzNiVWs0ZFdIZkJhR0t1QjJuN19CWnJwWjMwZEZTLWZuQlZlZFBvOXBmZFA5OWdjN3dNNmZDV2lKRmlfNzItVVI3cHJEMzEwX09Gam1TalZqOGFvUk12bmFkQVBTZUt5RVhJYUlhcEt6N3FTYW9TN0Z2ek8xejh2enZrQWN2anF6N3c1b1lseVhFYTFIR0FTcmhabHZCMExEQkRia21EaDRxMHluaGY5S01KQk1FM2oweEJqNGNCekhkRC12SHVuUmhjTUJaajJvT0FObWg0MWNibzZrN0RRYlN0bUNQUTY?oc=5", "source_name": "CRISPR Medicine News", "published_at": "2025-01-06T08:00:00+00:00", "published_display": "06 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JCR Pharmaceuticals and Modalis Therapeutics Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgJBVV95cUxNVzhaRlg0bkREUzFiRlFmSjhGTHJtejZOZ2lEdHJicFFiWV94eXpJVEs0SXBKVkFfamdoMnBodVRhRFpEWHZsbG5qdGVMZ1N1QlNHckxPSXd6c09fYzhPWURGWjFheGpiZjF3Z3hxX2hXUzVRcTNhYTZzOG4tc2xHaU5VYUw5QS1zQmtmTFVmenJVT1huVFNCZTlmeEFvSHAwRjlwNU9EYk1SUGp6ZEVzR3Vuck5JQ3NHOC1JVFRsSkh6X3RjNHdyQU42TkhqcnJpN1RBdzFKZlJzdGpJdkRDeE44b2tOZlJnN3owc1l4blJDM2NudjRsQU91Mm9FcjMxT0dvZEFxTWk4aDVlb2RRSHozeXhuU0pxcTExTkI2eXhYT0U4bUZ6VGx3S29LQQ?oc=5", "source_name": "Business Wire", "published_at": "2025-01-05T08:00:00+00:00", "published_display": "05 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release Service: Modalis Therapeutics: FDA Grants Rare Pediatric Disease Designation to MDL-101 for the Treatment of Congenital Muscular Dystrophy Type 1a (LAMA2-CMD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxOak1FRXdfYlVxMjlxekxjYmEtX3g0NnphOTRPWWNFRUV5WG1IOWVVQnhSekoza3JvT2lTWG1meDJCVjZuMnRISFhlRGZGamg0c2JmdDlDSldCWlpFQkd2WnBOMThMaXY4VDRKX2pGSlRxTmU3R3R1UF85a0xQMVhaVVRJcjJsOV9Hc21DeEVOZXpnRENRc1Mta1doamh5dFoyY0Y1UEwyZjBya3A4eEIyR3ZadXFCdThqU0JJNlJBWHVIdDJuQXVaZ0d3Z2F0dDBBV2xMQng3TzZCdGstcnp6bjgxeUc4b1NpSUFYdHhR?oc=5", "source_name": "CRISPR Medicine News", "published_at": "2024-09-30T07:00:00+00:00", "published_display": "30 Sep 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 52, "total_relevant": 6, "sentiment_summary": {"positive": 1, "negative": 0, "neutral": 5, "score": 55, "total": 6, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 85, "events": [{"event": "general", "label": "Market update", "weight": 3.3, "count": 6}], "positive_events": 1, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 33.0, "latest_week": "2026-07-10", "one_week_move": 0.0, "four_week_move": -2.9, "twelve_week_move": -38.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.172255, "market_dynamics_buy_signal": false, "relative_strength": -62.267447, "fair_value_gap": -64.5, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 34.0248, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.0% over one week, -2.9% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 56, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TipRanks", "count": 2}, {"label": "CRISPR Medicine News", "count": 2}, {"label": "Moomoo", "count": 1}, {"label": "Business Wire", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 6}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 6}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "85/100 classification confidence."}, {"label": "Company focus", "value": "6", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.0% over one week, -2.9% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Modalis Highlights CRISPR-GNDM Platform as Cornerstone of Rare Disease Growth Strategy"}], "updated_at": "2026-07-17T06:29:15.248567+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}